Compare DAWN & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DAWN | BCX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.7M | 750.9M |
| IPO Year | 2021 | N/A |
| Metric | DAWN | BCX |
|---|---|---|
| Price | $12.12 | $11.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $27.56 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 370.6K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.99% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $133,672,000.00 | N/A |
| Revenue This Year | $17.32 | N/A |
| Revenue Next Year | $53.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.11 | N/A |
| 52 Week Low | $5.64 | $8.25 |
| 52 Week High | $13.53 | $9.90 |
| Indicator | DAWN | BCX |
|---|---|---|
| Relative Strength Index (RSI) | 67.13 | 76.56 |
| Support Level | $10.16 | $10.78 |
| Resistance Level | $11.18 | $11.44 |
| Average True Range (ATR) | 0.81 | 0.18 |
| MACD | 0.20 | 0.04 |
| Stochastic Oscillator | 99.60 | 95.61 |
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.